chr11-78172809-A-C
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_001029859.3(KCTD21):c.*963T>G variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.412 in 152,338 control chromosomes in the GnomAD database, including 13,611 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.41 ( 13570 hom., cov: 31)
Exomes 𝑓: 0.42 ( 41 hom. )
Consequence
KCTD21
NM_001029859.3 3_prime_UTR
NM_001029859.3 3_prime_UTR
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -0.133
Publications
9 publications found
Genes affected
KCTD21 (HGNC:27452): (potassium channel tetramerization domain containing 21) Enables cullin family protein binding activity; histone deacetylase binding activity; and identical protein binding activity. Involved in negative regulation of smoothened signaling pathway and ubiquitin-dependent protein catabolic process. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.86).
BA1
GnomAd4 highest subpopulation (AMR) allele frequency at 95% confidence interval = 0.472 is higher than 0.05.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.412 AC: 62589AN: 151766Hom.: 13562 Cov.: 31 show subpopulations
GnomAD3 genomes
AF:
AC:
62589
AN:
151766
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.416 AC: 189AN: 454Hom.: 41 Cov.: 0 AF XY: 0.400 AC XY: 112AN XY: 280 show subpopulations
GnomAD4 exome
AF:
AC:
189
AN:
454
Hom.:
Cov.:
0
AF XY:
AC XY:
112
AN XY:
280
show subpopulations
African (AFR)
AC:
0
AN:
0
American (AMR)
AC:
0
AN:
0
Ashkenazi Jewish (ASJ)
AC:
0
AN:
0
East Asian (EAS)
AF:
AC:
1
AN:
2
South Asian (SAS)
AF:
AC:
2
AN:
2
European-Finnish (FIN)
AF:
AC:
162
AN:
398
Middle Eastern (MID)
AC:
0
AN:
0
European-Non Finnish (NFE)
AF:
AC:
21
AN:
48
Other (OTH)
AF:
AC:
3
AN:
4
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.482
Heterozygous variant carriers
0
5
10
15
20
25
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
GnomAD4 genome AF: 0.412 AC: 62630AN: 151884Hom.: 13570 Cov.: 31 AF XY: 0.409 AC XY: 30323AN XY: 74208 show subpopulations
GnomAD4 genome
AF:
AC:
62630
AN:
151884
Hom.:
Cov.:
31
AF XY:
AC XY:
30323
AN XY:
74208
show subpopulations
African (AFR)
AF:
AC:
11539
AN:
41432
American (AMR)
AF:
AC:
7287
AN:
15270
Ashkenazi Jewish (ASJ)
AF:
AC:
1866
AN:
3470
East Asian (EAS)
AF:
AC:
1730
AN:
5122
South Asian (SAS)
AF:
AC:
2117
AN:
4816
European-Finnish (FIN)
AF:
AC:
4192
AN:
10532
Middle Eastern (MID)
AF:
AC:
152
AN:
294
European-Non Finnish (NFE)
AF:
AC:
32363
AN:
67938
Other (OTH)
AF:
AC:
904
AN:
2106
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.501
Heterozygous variant carriers
0
1801
3603
5404
7206
9007
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
594
1188
1782
2376
2970
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
1321
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.